Uses of Eldosin 300mg

Eldosin 300mg drug with the main ingredient is Erdosteine ​​300mg is a medicine with the effect of loosening and dissolving mucus used in acute and chronic respiratory diseases. To better understand Eldosin 300mg and its uses, let's learn more in the article below.

Eldosin medicine has the main ingredient Erdosteine ​​300mg is a medicine with the effect of loosening and dissolving mucus used in acute and chronic respiratory diseases. The drug has the main ingredient is erdosteine ​​300mg, with a sufficient amount of excipients in 1 tablet such as microcrystalline cellulose, Povidone K-30, Magnesium stearate. The drug is made in the form of hard capsules, with a green cap and a yellow body.
Pharmacodynamic properties of the drug Eldosin 300mg The drug reduces the viscosity of mucus and purulent sputum. Erdosteine ​​is a prodrug, which becomes active after metabolism, thanks to which free thiol groups are formed.
This effect is due to the opening of disulfide bonds of bronchial mucoproteins. It has also been shown that erdosteine ​​inhibits bacterial adhesion to epithelial cells.
Pharmacokinetic properties of eldosin 300mg: Absorption
Erdosteine ​​is rapidly absorbed following oral administration and rapidly metabolized via first-pass metabolism to the biologically active metabolite - N- thiodiglycol-homocysteine ​​(M1).
After administration of 300 mg, the peak plasma concentration of erdosteine ​​(Cmax) - 1.26 ± 0.23 μg/ml - reached 1.18 ± 0.26 hours after administration (Tmax), in when M1 showed Cmax of 3.46 μg/ml and Tmax of 1.48 h.
Plasma concentrations of erdosteine ​​are dose-dependently increased. Plasma concentrations of M1 also increase with dose, but not proportionally as in the case of unchanged erdosteine. Food intake does not affect the absorption of eldosin.
Distribution
In animal models, Erdosteine ​​is distributed mainly into the kidneys, bones, spinal cord and liver. Pharmacologically active concentrations of both erdosteine ​​and M1 were found in Bronchoalveolar Lavage.
Elimination
T1⁄2 elimination is 1.46 ± 0.60 hours and 1.62 ± 0.59 hours for Erdosteine ​​and M1, respectively. Only M1 and sulphate were found in the urine, and the process of excretion through feces was not significant. After taking 600-900 mg daily for 8 days, one study observed no accumulation or metabolic changes of erdosteine ​​and M1.
Effect of age
Age has no effect on the pharmacokinetics of erdosteine.
Binding to plasma proteins
The drug binding of erdosteine ​​to plasma proteins is 64.5% (range: 50-86%).

2.1 Indications of the drug eldosin 300mg The drug has an expectorant effect, indicated for the treatment of acute exacerbations of chronic bronchitis in adults, cases of acute and chronic respiratory disease.
Each type of pharmaceutical product is designed to treat a specific disease or condition. That is why Eldosin Capsule should only be used to treat the conditions or conditions specified in the instructions for use.
2.2 Contraindications of Eldosin 300mg Hypersensitivity to the active substance or to any of the excipients of the drug. As there are no data in patients with creatinine clearance <25ml/min, or with severe hepatic impairment, the use of erdosteine ​​is not recommended in these patients. Patients with active peptic ulcer disease.

3.1. Usage – Dosage of eldosin 300mg The drug is to be taken orally, the capsules must be swallowed whole with a glass of water. Recommended dose: 2-3 times a day, 1 tablet each time
Dosage is for reference only. Dosage varies from person to person depending on the condition and progression of the disease. Consult your doctor or pharmacist for the right dosage.
There are no studies or data on overdosage of Eldosin. Do not exceed the recommended dose. In case of overdose, immediately go to a medical facility for care and treatment. In case of an emergency, call 911 or go to the nearest medical facility.
In case of missed dose, take Eldosin as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take your next dose as scheduled. Do not take a double dose at once to make up for a missed dose.
3.2. Precautions/precautions for use No increase in adverse events with erdosteine ​​has been observed in patients with mild hepatic impairment; However, these patients should not exceed 300 mg daily.
There are no studies on the use of eldosin in pregnant and lactating women. Therefore, eldosin is not recommended for these two subjects.
For the ability to drive and use machines: Eldosin has little or no effect on this subject.
3.3. Eldosin 300mg side effects

Above is all that is important about Eldosin 300mg pills. Knowing the use, dosage, and method of use will bring optimal results for the process of use.